
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is demonstrating a positive outlook due to the encouraging early data from its FREEDOM-DM1 trial, which showed a dose-dependent increase in splicing correction following treatment, achieving a notable 29.1% splicing correction, surpassing the therapeutic benefit threshold. The company's Enhanced Delivery Oligonucleotide (EDO) platform has proven effective in achieving significant tissue penetration and cellular uptake, with nearly a four-fold increase in oligonucleotide enrichment in muscle tissue when comparing different dosing levels. Additionally, the absence of safety issues reported at dosages tested reinforces confidence in the EDO platform and the overall potential of PepGen's pipeline, particularly for its DM1 program.
Bears say
PepGen Inc. reported a net loss of $22 million, or $0.68 per share, in the fourth quarter of 2024, indicating significant financial strain. The company has reduced its probability of success for its flagship product, PGN-EDO51, from 40% to 25% due to safety concerns related to kidney function, which also included the removal of a 15% premium related to its risk-reward profile. Key risks tied to PepGen's outlook involve the potential failure of PGN-EDO51 in clinical studies, obstacles to securing regulatory approval in both the US and EU, and the inability to meet projected peak commercial revenue estimates, all of which cast doubt on the company's future financial performance.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares